Tags

Type your tag names separated by a space and hit enter

The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
Curr Stem Cell Res Ther. 2021; 16(3):277-285.CS

Abstract

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since Dec 2019, known as COVID-19 or 19-nCoV, has led to a major concern of the potential for not only an epidemic but a pandemic in China and now it seems to be a public health problem all over the world. The general mortality rate of the COVID-19 was about 3%. However, the mortality risk seems to be a significant increase in elderly and cases with chronic disease, who are more likely to develop into acute respiratory distress syndrome (ARDS). There still lacks effective methods for ARDS of COVID-19 patients and the prognosis was poor. Mesenchymal Stem Cells (MSCs) based treatment has the advantage of targeting numerous pathophysiological components of ARDS by secreting a series of cell factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. Recently, pilot clinical studies indicated MSCs based therapy was promise in treatment of ARDS caused by SARS-CoV-2. However, little is known about MSCs therapy for ARDS caused by COVID-19.

Authors+Show Affiliations

National Engineering Research Center of Cell Products, Tianjin AmCellGene Engineering Co., Ltd, Tianjin, China.National Engineering Research Center of Cell Products, Tianjin AmCellGene Engineering Co., Ltd, Tianjin, China.National Engineering Research Center of Cell Products, Tianjin AmCellGene Engineering Co., Ltd, Tianjin, China.National Engineering Research Center of Cell Products, Tianjin AmCellGene Engineering Co., Ltd, Tianjin, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32729428

Citation

Gu, Jundong, et al. "The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused By COVID-19." Current Stem Cell Research & Therapy, vol. 16, no. 3, 2021, pp. 277-285.
Gu J, Zhao Q, Han Z, et al. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19. Curr Stem Cell Res Ther. 2021;16(3):277-285.
Gu, J., Zhao, Q., Han, Z., & Han, Z. (2021). The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19. Current Stem Cell Research & Therapy, 16(3), 277-285. https://doi.org/10.2174/1574888X15999200729161539
Gu J, et al. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused By COVID-19. Curr Stem Cell Res Ther. 2021;16(3):277-285. PubMed PMID: 32729428.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19. AU - Gu,Jundong, AU - Zhao,Qinjun, AU - Han,Zhibo, AU - Han,Zhongchao, PY - 2020/04/01/received PY - 2020/06/17/revised PY - 2020/06/23/accepted PY - 2020/7/31/pubmed PY - 2021/5/13/medline PY - 2020/7/31/entrez KW - ARDS KW - COVID-19 KW - Mesenchymal stem cell KW - SARS-CoV-2 KW - antiapoptotic KW - proangiogenic SP - 277 EP - 285 JF - Current stem cell research & therapy JO - Curr Stem Cell Res Ther VL - 16 IS - 3 N2 - The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since Dec 2019, known as COVID-19 or 19-nCoV, has led to a major concern of the potential for not only an epidemic but a pandemic in China and now it seems to be a public health problem all over the world. The general mortality rate of the COVID-19 was about 3%. However, the mortality risk seems to be a significant increase in elderly and cases with chronic disease, who are more likely to develop into acute respiratory distress syndrome (ARDS). There still lacks effective methods for ARDS of COVID-19 patients and the prognosis was poor. Mesenchymal Stem Cells (MSCs) based treatment has the advantage of targeting numerous pathophysiological components of ARDS by secreting a series of cell factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. Recently, pilot clinical studies indicated MSCs based therapy was promise in treatment of ARDS caused by SARS-CoV-2. However, little is known about MSCs therapy for ARDS caused by COVID-19. SN - 2212-3946 UR - https://www.unboundmedicine.com/medline/citation/32729428/The_Promise_of_Mesenchymal_Stem_Cells_Therapy_for_Acute_Respiratory_Distress_Syndrome_Caused_by_COVID_19_ L2 - https://www.eurekaselect.com/184327/article DB - PRIME DP - Unbound Medicine ER -